JM-20

JM-20 is a **novel small molecule drug** consisting of a benzodiazepine–dihydropyridine hybrid structure designed to provide multisite neuroprotective effects[1][2][3][7]. Developed at the Center for Research and Development of Medicines (CIDEM) in Cuba and the University of Havana, JM-20 acts on several neurodegenerative and neurological disease models including **cerebral ischemia, Alzheimer's disease, Parkinson's disease, and age-related cognitive decline**[2][5][7]. Its neuroprotective mechanisms include reduction of neuronal excitotoxic injury, protection against mitochondrial dysfunction, modulation of acetylcholinesterase activity, inhibition of glutamate-induced toxicity, prevention of mitochondrial permeability transition, and interference with alpha-synuclein aggregation[1][3][4][5]. JM-20 has shown beneficial effects in several preclinical models, improving behavioral, molecular, and morphological outcomes associated with neuronal injury[4][5][7].

Other names

3-ethoxycarbonyl-2-methyl-4-(2-nitrophenyl)-4,11-dihydro-1H-pyrido[2,3-b][1,5]benzodiazepine